Sergei Gryaznov
Chief Tech/Sci/R&D Officer at MAIA BIOTECHNOLOGY, INC.
Net worth: 119 289 $ as of 2024-04-29
Profile
Sergei M.
Gryaznov is the founder of Lynx Therapeutics, Inc. (founded in 1993).
He is currently the Chief Scientific Officer at MAIA Biotechnology, Inc. (since 2019).
Dr. Gryaznov previously worked as the Chemistry Director at Geron Corp.
(from 1998 to 2013) and as the Chief Technology Officer at Exicure Operating Co. Dr. Gryaznov holds graduate and doctorate degrees from Moscow State University Lomonosov.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
MAIA BIOTECHNOLOGY, INC.
0.22% | 2024-04-25 | 44,511 ( 0.22% ) | 119 289 $ | 2024-04-29 |
Sergei Gryaznov active positions
| Companies | Position | Start |
|---|---|---|
| MAIA BIOTECHNOLOGY, INC. | Chief Tech/Sci/R&D Officer | 2019-11-30 |
Former positions of Sergei Gryaznov
| Companies | Position | End |
|---|---|---|
| GERON CORPORATION | Corporate Officer/Principal | 2012-12-31 |
Lynx Therapeutics, Inc.
 Lynx Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Lynx Therapeutics, Inc. was a developer of genetic analysis products for the pharmaceutical, biotechnology and agriculture industries. It's MPSSTM instruments analyze millions of DNA molecules in parallel enabling genome structure characterization at an unprecedented level of resolution. MPSSTM provides comprehensive and quantitative digital information important to modern systems biology research in the pharmaceutical, biotechnology and agricultural industries. The company was headquartered in Hayward, CA. | Corporate Officer/Principal | 1996-12-31 |
Exicure Operating Co.
 Exicure Operating Co. Pharmaceuticals: MajorHealth Technology Exicure Operating Co. operates as a biopharmaceutical company commercializing spherical nucleic acid constructs as gene regulation and modulation agents for diseases including applications in oncology, dermatology, neurology, and for immune disorders. The SNA constructs allow the use of oligonucleotide-based therapies to treat diseases in a range of tissue types. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL. | Chief Tech/Sci/R&D Officer | - |
Training of Sergei Gryaznov
| Moscow State University Lomonosov | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| GERON CORPORATION | Health Technology |
| MAIA BIOTECHNOLOGY, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Exicure Operating Co.
Exicure Operating Co. Pharmaceuticals: MajorHealth Technology Exicure Operating Co. operates as a biopharmaceutical company commercializing spherical nucleic acid constructs as gene regulation and modulation agents for diseases including applications in oncology, dermatology, neurology, and for immune disorders. The SNA constructs allow the use of oligonucleotide-based therapies to treat diseases in a range of tissue types. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL. | Health Technology |
Lynx Therapeutics, Inc.
Lynx Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Lynx Therapeutics, Inc. was a developer of genetic analysis products for the pharmaceutical, biotechnology and agriculture industries. It's MPSSTM instruments analyze millions of DNA molecules in parallel enabling genome structure characterization at an unprecedented level of resolution. MPSSTM provides comprehensive and quantitative digital information important to modern systems biology research in the pharmaceutical, biotechnology and agricultural industries. The company was headquartered in Hayward, CA. | Health Technology |
- Stock Market
- Insiders
- Sergei Gryaznov
